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A site-selective CAMP analog, S-chloroadenosine 3’,5’cyclic monophosphate (8-Cl-cAMP), was demonstrated to be a 
potent inhibitor of both the monolayer and soft agar growth of normal rat kidney @IRK) fibroblasts that had been trans- 
formed with the v-Ki-ras oncogene or treated with transforming growth factor a (TGFa). The growth inhibition was 
dose dependent and reversible and was accompanied by reversion of the transformed phenotype, suppression of TGFa 
production, and a decrease in p2lras protein levels. These effects of 8-Cl-cAMP were linked to the CAMP analog’s electi- 
ve modulation of the type I and type II cAMPdependent protein kinase regulatory subunits, RI and RII, present in 
Ki-rur-transformed and TGFa-treated NRK cells. 
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1. INTRODUCTION 
We previously reported that new site-selective 
CAMP analogs produce potent growth inhibition 
and differentiation in a variety of cancer cell lines 
[l-5]. These CAMP analogs exert their biological 
effects by provoking a differential regulation of 
type I versus type II CAMP-dependent protein 
kinase isozymes [l-5]. We have also demonstrated 
that CAMP-induced reversion of the transformed 
phenotype and growth inhibition leads to a sup- 
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pression in p2lras expression [1,4,5]. TGFcv is a 
potent mitogen for fibroblasts and epithelial cells 
[6] that has been circumstantially implicated in the 
autocrine growth of a variety of transformed cells. 
Enhanced synthesis and secretion of TGFa have 
been demonstrated in a number of rodent and 
human tumor cell lines and in oncogene- 
transformed rodent fibroblasts and epithelial cells 
[7-121. In the present work, we investigated the 
ability of 8-Cl-CAMP (which has been selected by 
the National Cancer Institute as preclinical phase I 
antineoplastic drug) to antagonize the effects of 
exogenous TGFcv in NRK fibroblasts and to inhibit 
the production of TGFa by Ki-ras-transformed 
NRK (K-NRK) cells. 
2. MATERIALS AND METHODS 
8-Cl-CAMP was synthesized at the Nucleic Acid Research In- 
stitute (Costa Mesa, CA) [13]. Synthetic TGFcv was purchased 
from Bachem (Torrance, CA). A clone, 49F, of NRK cells was 
obtained from Dr J. DeLarco (NCI, Bethesda, MD) and K- 
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NRK cells (NRK cells transformed by the viral Kirsten rus on- 
cogene) were a gift from Dr R.H. Bassin (NCI, Bethesda). The 
cells were grown in DMEM supplemented with 10% FBS, 
100 U/ml penicillin, 100 /g/ml streptomycin (Gibco, Grand 
Island, NY) in a 5% humidified atmosphere at 37’C. 
For cell growth experiments in monolayer culture, 1 x 16 
cells/60 mm dish were seeded in DMEM containing 10% FBS, 
and 24 h later (day 0) medium was changed and TGFa 
(5 ng/ml) was added. Fresh medium was added every 48 h 
thereafter. 8-Cl-CAMP was added at the time of medium 
replenishment starting day zero. At the indicated times, cells 
were harvested and cell counts were performed in duplicate on 
a ZBI Coulter counter (Coulter Electronics, Hialeah, FL). 
For experiments in soft agar, 2 x 104 cells/35 mm dish were 
seeded into 0.3% Difco Noble agar supplemented with DMEM 
containing 10% FBS, layered over a base layer of 0.8% agar 
medium, and treated with a variety of concentrations of 8-Cl- 
CAMP. After 12 days, cells were stained with Nitro blue 
tetrazolium, and colonies larger than 50 pm were counted with 
an Artek 880 colony counter (Artek Systems, Inc., Farm- 
ingdale, NY). 
Preparation of conditioned media from cultured cells and 
determination of TGFm by RIA and by RRA were performed 
as previously described [ 1 l- 141. 
Western blot analysis of p2lra.s was performed using 
Yl3-259, a rat monoclonal anti-p21 antibody, as previously 
described [15,16]. 
The levels of RI and RI1 regulatory subunits of CAMP- 
dependent protein kinase were determined by applying the 
photoaffinity labeling technique to the nuclear and cytosolic 
fractions of cell extracts as previously described [17]. 
3. RESULTS AND DISCUSSION 
8-Cl-CAMP, the most potent site-selective 
CAMP analog [l], was tested for its effect on the 
growth of Ki-ras-transformed K-NRK cells, and 
the results are shown in fig. 1A. At a concentration 
of lOpM, the CAMP analog inhibited growth by 
approx. 20% at day 2 and by 40% at day 7 when 
compared to the untreated control cells. At a 
higher concentration (50 PM), 8-Cl-CAMP in- 
hibited growth by 50% as early as day 3, and no 
cell growth was observed thereafter (fig.lA). In 
agreement with our previously reported results [4], 
the effect of 8-Cl-CAMP was cytostatic and reversi- 
ble, as shown by the resumption in cell growth 
after analog removal (fig. 1A). 
It has been shown [ 181 that TGF~Y can induce 
phenotypic transformation of NRK fibroblasts 
grown in the presence of serum containing TGF,& 
and other growth factors. Addition of TGFcv 
(5 ng/ml) to NRK cells produces a dramatic in- 
crease in cell growth in monolayer culture and in- 
duces morphological alterations typical of 
transformed phenotype, as is observed in ras- 
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transformed K-NRK cells [19,20]. In addition, 
NRK cells treated with TGFa exhibit anchorage- 
independent growth in semi-solid agar medium 
[20,21]. 
The addition of 50 PM 8-Cl-CAMP to NRK cells 
that were treated with TGFa in a monolayer 
culture resulted in a 60% inhibition of TGFa- 
stimulated growth by day 4 (fig. 1B) and induced a 
reversion of the morphological effects produced by 
TGFcv (fig.2, panel D). Interestingly, 8-Cl-CAMP 
did not inhibit the growth of NRK cells in the 
absence of TGFcu; rather, it slightly stimulated 
growth. A greater degree of growth inhibition was 
observed, in a dose-dependent fashion, on the 
TGFcu-induced soft agar growth of NRK cells 
(fig. 1C). 8-Cl-CAMP at 50 PM resulted in 80% in- 
hibition of TGFa-stimulated colony formation. 
We next investigated whether the growth in- 
hibitory effects of 8-Cl-CAMP on K-NRK cells are 
associated with a specific interference with the pro- 
duction of endogenous TGFcr. Conditioned 
medium was collected from K-NRK and NRK 
cells, and the levels of immunorective and 
biologically active TGFa were measured by RIA 
and RRA, respectively. As shown in fig.3A, both 
immunoreactive and biologically active TGFa 
were reduced by approx. 50% within 2 days of 
8-Cl-CAMP treatment. Thus, the decrease in TGF~Y 
production precedes or is at least concomitant with 
the inhibition of cell growth (fig. 1A) that follows 
8-Cl-CAMP treatment. Transformation of mouse 
mammary epithelial cells or NIH3T3 cells by an ac- 
tivated ras cellular proto-oncogene or v-Ki-ras 
leads to a lack of response by these cells to ex- 
ogenous TGFcv or EGF as a consequence of the in- 
creased capacity of these cells to secrete high levels 
of endogenous TGFa into the culture medium 
[11,14,22]. 
In a previous report we noted that 8-Cl-CAMP 
leads to a suppression of p2lras expressiop in 
several cancer cell lines [1,4,5]. We therefore in- 
vestigated by Western blotting analysis the effect 
of 8-Cl-CAMP on p2lras expression in K-NRK 
cells and in NRK cells stimulated with exogenous 
TGFcu. As shown in fig.3B, treatment of K-NRK 
cells with 50 PM 8-C&AMP resulted in a marked 
decrease in the levels of p2lras protein. Quan- 
tification by densitometry showed that the p21 
levels decreased to 50% of untreated control cell 
level within 2 days of 8-Cl-CAMP treatment (not 
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Fig. 1. Effect of S-Cl-CAMP on the growth of K-NRK cells, NRK cells, and NRK cells treated with TGFcy. (A) Monolayer growth of 
K-NRK cells; (B) monolayer growth of NRK cells; (C) soft agar growth of K-NRK cells and NRK cells treated with TGF~Y. Data 
represent an average f SD from four experiments. Colonies in the untreated controls were: K-NRK, 1280 (k 55) colonies/dish and 
NRK + TGFa (5 ng/ml), 1195 ( f 70) colonies/dish. 
A, Control; B, &Cl-CAMP (50pM); C, TOFU (5 nglml); 
D, TGFa (5 nglml) + 8-Cl-CAMP (5OpM) 
Fig.2. Effect of 8-Cl-CAMP and TGFL~ on the morphology of 
NRK cells. (A) Untreated control cells; (B) treatment of cells for 
4 days with 8-Cl-CAMP (50,uM); (C) TGFcv (5 ng/ml); (D) 
TGFcv (5 ng/ml) + 8-Cl-CAMP (50,uM). x 125. 
shown). Thus, the decreases in endogenous TGFa 
production and in p2lras protein levels occur 
simultaneously and precede the growth arrest and 
morphological changes in K-NRK cells following 
8-Cl-CAMP treatment. Moreover, we found that 
the addition of TGFa (5 ng/ml) to NRK cells 
resulted in the appearance of endogenous p2lras, 
which was at an undetectable level in the untreated 
control cells, and the treatment with 8-Cl-CAMP 
sharply reduced the p21 level (not shown). 
It has been shown that the expression of the type 
I isozyme of the CAMP-dependent protein kinase 
and its regulatory subunit, RI, is associated with 
an increase in cell proliferation and with neoplastic 
transformation, whereas an increase in the levels 
of the type II protein kinase and its regulatory 
subunit, RII, is linked to cellular growth inhibition 
and differentiation [ 15,23,25]. We recently 
demonstrated that the antineoplastic activity of 
B-Cl-CAMP is associated with an early increase 
365 
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A 
TGFa in the conditioned media 
Cells Treatment (ng/lO’ cells148 hr) 
RIA RRA 
NRK none 20 k 3.0 22 * 1.0 
K-NRK none 284 + 12 (100) 200 + 20 (100) 
K-NRK 8-Cl-CAMP 128 k 17 (49) 143 -e 5 (57) 
(2 days) 








Fig.3. Effect of 8-U-CAMP on TGFu production and p2lras 
protein levels in K-NRK cells. (A) TGFcz protein from 
concentrated conditioned medium was evaluated in a TGF~Y- 
specific RIA and in an EGF/TGFa RRA as previously 
described [11,14]. Values represent he mean + SD from four 
experiments. Values in parentheses are the percentages. (B) 
Western blotting of ~21 protein was performed as previously 
described [15,16]. M, marker proteins of known molecular 
mass (Bethesda Research Laboratories). V, cell lysate from Ha- 
MuSV-transformed NIH3T3 clone 13-3-B4 [2]. 
(within 10 min) of RI1 in the nucleus of treated 
LS-174T human colon cancer cells [ 171. We 
therefore measured the levels of the RI and RI1 
regulatory subunits in the cytosolic and nuclear 
fractions of K-NRK and NRK cells, using a 
8-N3-[32P]cAMP photoaffinity ligand. As shown 
in fig.4, in K-NRK cells treatment with 50 ,uM of 
8-Cl-CAMP brought about a marked reduction of 
RI level in nuclei and an increase of RI1 levels in 
both the cytosol and nuclei (lanes 9-12). In NRK 
cells, the addition of TGFcz resulted in a marked 
increase of RI levels in both the cytosol and nuclei 
(lanes 3 and 7), thereby mimicking the effect of ras 
transformation (lanes 9 and 11). The addition of 
8-Cl-CAMP to TGFa-treated NRK cells markedly 
reduced the RI levels in both the cytosol and nuclei 
(lanes 4 and 8). Concomitantly, RI1 levels in- 
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Fig.4. Effect of 8-Cl-CAMP and TGF~Y on the levels of RI and 
RI1 CAMP receptor proteins in the cytosol (Sp) and nuclei (N) 
of NRK cells and K-NRK cells. Photoactivated incorporation of 
8-Ns-[32P]cAMP on the nuclear and the cytosolic fractions was 
performed as previously described [17]. RI, the 48-kDa RI 
CAMP receptor protein; RII, the 56-kDa RI1 CAMP receptor 
protein (Sigma Chemical Co., St. Louis, MO). 
nucleus (lanes 4 and 8), where there was an inver- 
sion in the RI/RI1 ratio as compared with that in 
untreated cells. Interestingly, treatment with 8X1- 
CAMP alone, which did not inhibit growth in NRK 
cells (fig.lB), had no appreciable effect upon the 
levels of RI or RI1 in comparison with untreated 
cells (cf. lanes 2 and 6 with 1 and 5). 
The results of this study represent, to our 
knowledge, the first evidence demonstrating a 
direct role for a CAMP analog, 8-C&AMP, in the 
control of TGFcv production and activity in 
transformed fibroblasts. We have shown that 8-Cl- 
CAMP inhibits the growth of ras-transformed K- 
NRK cells and of TGFa-treated NRK cells, both in 
monolayer and soft agar cultures. Growth inhibi- 
tion was accompanied by a reduction in TGFcv pro- 
duction and inhibition of the p2lras level in 
K-NRK cells. Furthermore, these effects of 8-Cl- 
CAMP appear to be related to a selective modula- 
tion of the levels of RI versus RI1 CAMP receptor, 
the regulatory subunits of protein kinase isozymes 
present in these cells (namely, a decrease in the RI 
level and a nuclear translocation of RII). These 
data strongly support the role of 8-Cl-CAMP as an 
antiproliferative and differentiating antineoplastic 
366 
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drug and directly implicate it in the control of 
neoplastic transformation induced by certain 
growth factors and/or specific oncogenes. 
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